+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Attention Deficit Hyperactivity Disorder (ADHD) Treatment

  • ID: 4857811
  • Report
  • October 2019
  • Region: Global
  • 141 pages
  • Syngene Research
1 of 3

Enquire about COVID-19 updates for this product.

Enquire Now

FEATURED COMPANIES

  • Alcobra
  • Eli Lilly and Company
  • Mallinckrodt
  • Neurovance
  • Noven Pharmaceuticals
  • Recordati
  • MORE
The Global Attention Deficit Hyperactivity Disorder (ADHD) Treatment market is expected to reach $34.10 billion by 2026 growing at a CAGR of 7.7% during the forecast period. ADHD is a complex neurological disorder which creates difficulty for a person in paying attention and in controlling their behaviour. The symptoms of ADHD might vary from person to person, but the most common symptoms include restlessness, difficulty in paying attention, hyperactivity, frequent mood swings and difficulty in coping with stress. The most common factors which cause ADHD in people include exposure to environmental toxins such as high levels of lead at a young age, low birth weight, genes, brain injuries, etc.

Increasing awareness regarding neuro-developmental disorders and easy availability of diagnostic guidelines over the internet is projected to boost the growth. However, underdiagnosis of ADHD due to the existence of comorbid conditions in children, lack of awareness and low availability of non-stimulant drugs to treat ADHD in various regions are likely to hamper the expansion of the global ADHD therapeutics market during the forecast period.

Based on the Age Group, the Adults segment is estimated to have a lucrative growth due to the high prevalence of the condition across the globe, increased awareness about mental health, and launch of effective drugs with minimum adverse effects.

The key vendors mentioned are Alcobra, Amarantus, Curemark, Eli Lilly and Company, Highland Therapeutics, Johnson & Johnson Services, LLC, Lupin, Mallinckrodt, Medice, NEOS Therapeutics Inc., Neurovance, Nextwave Pharmaceuticals, Novartis AG, Noven Pharmaceuticals, Pfizer, Prude Pharma L.P., Recordati, Rhodes Pharmaceuticals, Shionogi, and Shire.

Drugs Covered:
  • Amphetamine
  • Atomoxetine
  • Bupropion
  • Clonidine
  • Dexmethylphenidate
  • Guanfacine
  • Lisdexamfetamine
  • Methylphenidate
  • Dextroamphetamine
Types Covered:
  • Non-Stimulants
  • Stimulants
Age Groups Covered:
  • Adult (Aged 18 and above)
  • Children (2-17 years of age)
  • Paediatric and Adolescent
Distribution Channels Covered:
  • E-Commerce
  • Hospital Pharmacy
  • Retail Pharmacy
  • Speciality Clinics
Regions Covered:
  • North America
  • Europe
  • Asia Pacific
  • South America
  • Middle East & Africa
Key Questions Answered in this Report:
  • How this market evolved since the year 2016
  • Market size estimations, forecasts and CAGR for all the segments presented in the scope
  • Key Market Developments and financials of the key players
  • Opportunity Analysis for the new entrants
  • SWOT Analysis of the key players
  • Fastest growing markets analyzed during the forecast period

*Please Note: This report will be delivered within 48 hours of ordering.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Alcobra
  • Eli Lilly and Company
  • Mallinckrodt
  • Neurovance
  • Noven Pharmaceuticals
  • Recordati
  • MORE
1 Market Synopsis

2 Research Outline
2.1 Research Snapshot
2.2 Research Methodology
2.3 Research Sources
2.3.1 Primary Research Sources
2.3.2 Secondary Research Sources

3 Market Dynamics
3.1 Drivers
3.2 Restraints

4 Market Environment
4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry

5 Global Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market, By Drug
5.1 Introduction
5.2 Amphetamine
5.3 Atomoxetine
5.4 Bupropion
5.5 Clonidine
5.6 Dexmethylphenidate
5.7 Guanfacine
5.8 Lisdexamfetamine
5.9 Methylphenidate
5.10 Dextroamphetamine

6 Global Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market, By Type
6.1 Introduction
6.2 Non-Stimulants
6.3 Stimulants

7 Global Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market, By Age Group
7.1 Introduction
7.2 Adult (Aged 18 and above)
7.3 Children (2-17 years of age)
7.4 Pediatric and Adolescent

8 Global Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market, By Distribution Channel
8.1 Introduction
8.2 E-Commerce
8.3 Hospital Pharmacy
8.4 Retail Pharmacy
8.5 Specialty Clinics

9 Global Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market, By Geography
9.1 North America
9.2 Europe
9.3 Asia Pacific
9.4 South America
9.5 Middle East & Africa

10 Strategic Benchmarking

11 Vendors Landscape
11.1 Alcobra
11.2 Amarantus
11.3 Curemark
11.4 Eli Lilly and Company
11.5 Highland Therapeutics
11.6 Johnson & Johnson Services, LLC
11.7 Lupin
11.8 Mallinckrodt
11.9 Medice
11.10 NEOS Therapeutics Inc.
11.11 Neurovance
11.12 Nextwave Pharmaceuticals
11.13 Novartis AG
11.14 Noven Pharmaceuticals
11.15 Pfizer
11.16 Prude Pharma L.P.
11.17 Recordati
11.18 Rhodes Pharmaceuticals
11.19 Shionogi
11.20 Shire

List of Data Tables
Table 1 Global Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market Outlook, By Region (2016-2026) ($MN)
Table 2 Global Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market Outlook, By Drug (2016-2026) ($MN)
Table 3 Global Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market Outlook, By Amphetamine (2016-2026) ($MN)
Table 4 Global Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market Outlook, By Atomoxetine (2016-2026) ($MN)
Table 5 Global Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market Outlook, By Bupropion (2016-2026) ($MN)
Table 6 Global Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market Outlook, By Clonidine (2016-2026) ($MN)
Table 7 Global Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market Outlook, By Dexmethylphenidate (2016-2026) ($MN)
Table 8 Global Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market Outlook, By Guanfacine (2016-2026) ($MN)
Table 9 Global Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market Outlook, By Lisdexamfetamine (2016-2026) ($MN)
Table 10 Global Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market Outlook, By Methylphenidate (2016-2026) ($MN)
Table 11 Global Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market Outlook, By Dextroamphetamine (2016-2026) ($MN)
Table 12 Global Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market Outlook, By Type (2016-2026) ($MN)
Table 13 Global Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market Outlook, By Non-Stimulants (2016-2026) ($MN)
Table 14 Global Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market Outlook, By Stimulants (2016-2026) ($MN)
Table 15 Global Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market Outlook, By Age Group (2016-2026) ($MN)
Table 16 Global Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market Outlook, By Adult (Aged 18 and above) (2016-2026) ($MN)
Table 17 Global Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market Outlook, By Children (2-17 years of age) (2016-2026) ($MN)
Table 18 Global Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market Outlook, By Pediatric and Adolescent (2016-2026) ($MN)
Table 19 Global Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market Outlook, By Distribution Channel (2016-2026) ($MN)
Table 20 Global Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market Outlook, By E-Commerce (2016-2026) ($MN)
Table 21 Global Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market Outlook, By Hospital Pharmacy (2016-2026) ($MN)
Table 22 Global Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market Outlook, By Retail Pharmacy (2016-2026) ($MN)
Table 23 Global Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market Outlook, By Specialty Clinics (2016-2026) ($MN)
Table 24 North America Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market Outlook, By Drug (2016-2026) ($MN)
Table 25 North America Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market Outlook, By Type (2016-2026) ($MN)
Table 26 North America Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market Outlook, By Age Group (2016-2026) ($MN)
Table 27 North America Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market Outlook, By Distribution Channel (2016-2026) ($MN)
Table 28 Europe Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market Outlook, By Drug (2016-2026) ($MN)
Table 29 Europe Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market Outlook, By Type (2016-2026) ($MN)
Table 30 Europe Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market Outlook, By Age Group (2016-2026) ($MN)
Table 31 Europe Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market Outlook, By Distribution Channel (2016-2026) ($MN)
Table 32 Asia Pacific Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market Outlook, By Drug (2016-2026) ($MN)
Table 33 Asia Pacific Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market Outlook, By Type (2016-2026) ($MN)
Table 34 Asia Pacific Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market Outlook, By Age Group (2016-2026) ($MN)
Table 35 Asia Pacific Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market Outlook, By Distribution Channel (2016-2026) ($MN)
Table 36 South America Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market Outlook, By Drug (2016-2026) ($MN)
Table 37 South America Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market Outlook, By Type (2016-2026) ($MN)
Table 38 South America Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market Outlook, By Age Group (2016-2026) ($MN)
Table 39 South America Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market Outlook, By Distribution Channel (2016-2026) ($MN)
Table 40 Middle East & Africa Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market Outlook, By Drug (2016-2026) ($MN)
Table 41 Middle East & Africa Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market Outlook, By Type (2016-2026) ($MN)
Table 42 Middle East & Africa Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market Outlook, By Age Group (2016-2026) ($MN)
Table 43 Middle East & Africa Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market Outlook, By Distribution Channel (2016-2026) ($MN)
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Alcobra
  • Amarantus
  • Curemark
  • Eli Lilly and Company
  • Highland Therapeutics
  • Johnson & Johnson Services, LLC
  • Lupin
  • Mallinckrodt
  • Medice
  • NEOS Therapeutics Inc.
  • Neurovance
  • Nextwave Pharmaceuticals
  • Novartis AG
  • Noven Pharmaceuticals
  • Pfizer
  • Prude Pharma L.P.
  • Recordati
  • Rhodes Pharmaceuticals
  • Shionogi
  • Shire
Note: Product cover images may vary from those shown
Adroll
adroll